Editas Medicine

📍 Cambridge, United States🗓 Founded 2013👥 331 employees💰 Last funded Oct 2021
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a clinical stage genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Our goal is to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.
3
Total investors
0
Early stage
1
Mid stage
2
Late stage
2013
Founded
Investor geography1 country
United States
3
Investor activity2018–2021 · investors recorded per year
201812020120211
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Editas Medicine?
Editas Medicine has 3 investors on record on gritt.io, 1 mid-stage and 2 late-stage investors.
When did Editas Medicine last raise funding?
The most recent investment in Editas Medicine recorded on gritt.io was in October 2021.
When was Editas Medicine founded?
Editas Medicine was founded in 2013.
What industry is Editas Medicine in?
Editas Medicine operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Editas Medicine based?
Editas Medicine is headquartered in Cambridge, United States.